Treatment Adherence and its Association to Quality of Life among Patients with Hypertension
Main Article Content
Background: Chronic diseases require long-term adherence to treatment is important for the control of disease as well as prevention of complications. Non-adhere may lead to worsening of the disease, which may affect patients' quality of life. This study aimed to assess the quality of life and its relationship to treatment adherence among patients with hypertension.
Methods: A descriptive correlational study conducted in Diwaniyah city during the period from October 1st 2022 to March 8th 2023. The study sample consist of 200 patients is selected according to non probability sampling approach. The validity of the questionnaire was verified by experts and its reliability was verified through a pilot study. The total number of items included in the questionnaire was 26 items to assess quality of life and 14 items to assess treatment adherence. Data were collected through the interview and analyzed by applying descriptive and inferential statistical analysis
Results: The results indicated that the average age of the respondents is 47.67 years, (56.5%) were female, (62%) were married, (43.5%) college graduated and (55%) government employ. Over than half (70.5%) of the study participants were found to average quality of life and (57%) were low adherence. There were positive correlation between treatment adherence quality of life.
Conclusions: The results showed that mean treatment adherence of respondents was within low level, and the quality of life was within average level. Statistical significance association was found between treatment adherence and quality of life. The study adds knowledge regarding health education for all segments of society towards treatment adherence among patients with hypertension. Further study is needed to explore strategies that maintain therapeutic adherence among patients in order to improve their quality of life.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.